These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 3178156)
21. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA]. Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273 [TBL] [Abstract][Full Text] [Related]
22. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478 [TBL] [Abstract][Full Text] [Related]
23. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644 [TBL] [Abstract][Full Text] [Related]
24. [Serum concentrations of the MCA tumor marker during pregnancy]. Pütz I; Lang G; Winkler M; Rath W Zentralbl Gynakol; 1996; 118(7):409-11. PubMed ID: 8766103 [TBL] [Abstract][Full Text] [Related]
25. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients. Cohen AD; Gopas J; Karplus G; Cohen Y Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585 [TBL] [Abstract][Full Text] [Related]
26. [Carcinoembryonic antigen (CEA) and mucinous-like tumor associated antigen (MAC). Statistic correlation in advanced breast carcinoma]. Sbalzarini G; D'Agostino F; Mercantini F; Girami M; Labadini A; Pandolfi C Minerva Med; 1991 Dec; 82(12):811-3. PubMed ID: 1780086 [TBL] [Abstract][Full Text] [Related]
27. [Sensitivity and specificity of CEA, Ca 15-3 and MCA levels in visceral breast carcinoma metastasis]. Delbrück H; Hagen-Aukamp C; Braun G Strahlenther Onkol; 1990 Jul; 166(7):457-9. PubMed ID: 2200152 [TBL] [Abstract][Full Text] [Related]
28. [Level of CA 15-3 antigen--a prognostic factor in patients with breast cancer?]. Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M Przegl Lek; 1996; 53(11):788-92. PubMed ID: 9173440 [TBL] [Abstract][Full Text] [Related]
29. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation. Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728 [TBL] [Abstract][Full Text] [Related]
30. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243 [TBL] [Abstract][Full Text] [Related]
31. [MSA--a new sensitive tumor marker in breast carcinoma]. Zahm DM; Greinke C; Nöschel H Zentralbl Gynakol; 1996; 118(12):659-64. PubMed ID: 9082702 [TBL] [Abstract][Full Text] [Related]
32. Serum markers for breast cancer. Stenman UH; Heikkinen R Scand J Clin Lab Invest Suppl; 1991; 206():52-9. PubMed ID: 1947760 [TBL] [Abstract][Full Text] [Related]
33. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer? Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651 [TBL] [Abstract][Full Text] [Related]
34. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors. Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573 [TBL] [Abstract][Full Text] [Related]
35. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA. Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258 [TBL] [Abstract][Full Text] [Related]
37. [Clinical evaluation of tumor markers in breast cancer patients]. Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907 [TBL] [Abstract][Full Text] [Related]
38. [Clinical usefulness of tumor markers in breast cancer]. Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956 [TBL] [Abstract][Full Text] [Related]
39. [Tumor markers in the diagnosis and prognosis of breast cancer]. Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study. Wojtacki J; Dziewulska-Bokiniec A; Skokowski J; Ciesielski D Neoplasma; 1994; 41(4):213-6. PubMed ID: 7935994 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]